Medical technologies

Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS will now go by Johnson & Johnson MedTech The planned transition has no impact on the Company’s products

Innovative system, now available in the U.S., offers strength, speed and contourability,1-4, ‡,§,¶,||#, addressing critical patient need in cardiac procedures3,4

V-Wave’s Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular

Inaugural National Heart Recovery Day Slated for 2025

Comprehensive, low-profile plating system designed specifically for foot and ankle surgeons will now be available across the U.S.

Labeling update for the LINX Reflux Management System will provide more patients relief from gastroesophageal reflux disease (GERD). Amendment is based on study results that found LINX™ to be safe and effective at treating GERD in patients with Barrett’s esophagus (BE).

The dual-use robotics and standalone navigation platform will become part of the VELYS™ Enabling Technologies Portfolio and integrate with existing J&J MedTech Spine products

New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and accuracy1 in the electro-anatomical maps electrophysiologists use in catheter ablation procedures

Company to present, across eight data presentations, new real-world research on the economic value of genetic testing for retinal diseases and the role of automatic deep-learning based algorithms for geographic atrophy Johnson & Johnson to debut first-of-its-kind EYE-RD Global Registry, aiming to bridge knowledge gaps for inherited retinal diseases